Compare ADMA Biologics Inc (ADMA) vs ING Groep NV (ING) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
ADMA Biologics Inc vs ING Groep NV — how do they compare? ADMA Biologics Inc trades at $9.18 (market cap $2.13B), while ING Groep NV trades at $31.94 (market cap $92.35B). The key difference: ING Groep NV is far larger — about 43.4× ADMA Biologics Inc's market cap, and ING Groep NV pays a 3.93% dividend while ADMA Biologics Inc pays none. Which is the better fit depends on your goals.
| ADMA | ING | |
|---|---|---|
Market Cap | $2.13B | $92.35B |
Sector | Health | Financials |
52-Week High | $20.38 | $32.96 |
52-Week Low | $7.60 | $22.45 |
Enterprise Value | $2.20B | — |
Dividend Yield | — | 3.93% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADMA trades at $9.16, up 2.35% today, with a bullish technical signal from moving averages and oscillators. The company reported strong profitability with a 32.43% net income margin and 43.3% ROE for 2025, though recent EPS results were mixed. Analyst consensus is strongly bullish with an $19.00 price target, but multiple class action lawsuits filed in July 2026 alleging securities fraud create significant near-term uncertainty.
The stock offers substantial upside to analyst targets if legal challenges are resolved favorably, supported by robust fundamentals and projected cash flow growth. Primary risks include the outcome of ongoing litigation and potential reputational damage. Investors should weigh strong financial performance against elevated legal and sentiment risks before establishing a position.
ING trades at $32.24, up 0.44% today, with a bullish technical outlook supported by moving averages. The stock shows consistent earnings beats and a 27.84% net income margin. Recent news highlights strategic moves like a global subscription banking model and board appointments, reinforcing growth initiatives. Analyst consensus is strongly positive with 62.5% buy ratings.
The outlook remains favorable due to solid fundamentals and bullish sentiment, though risks include volatile cash flows and macroeconomic pressures. Upside potential is supported by a DCF intrinsic value of $34, suggesting modest appreciation from current levels. Investors should weigh strong profitability against sector-specific headwinds.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About ADMA Biologics Inc
ADMA Biologics is a biopharmaceutical company specializing in plasma-derived therapies for immunodeficient patients. Key products like ASCENIV and BIVIGAM treat primary humoral immunodeficiency and help prevent infectious diseases.
Read more on ADMA →About ING Groep NV
The merger of the Dutch postal bank and NN Insurance in 1991 created ING. Through a series of further acquisitions ING build up a global footprint. The 2008 financial crisis forced ING to seek government support--a precondition of which was that ING should separate its banking and insurance activities, which saw ING revert to being solely a bank. ING has market- leading banking operations in the Netherlands and Belgium, and a range of digital banks across Europe and Australia. Its global wholesale banking operation is primarily focused on lending.
Read more on ING →
